This syringe technology developed under its product name "ChaSyr," (pronounced chaser), allows for the sequential administration of two separate intravenous (IV) medications with a single syringe, replacing multiple syringes with just one.
The benefits and capability of this single delivery multi-chamber syringe includes:
- increasing the speed and ease of drug administration
- reducing risk of hospital acquired infection by reducing the number of connections
- lowering the risk of drug administration or sequence errors
- quicker delivery of emergency medicines requiring an immediate sequential flush.
Merle Ferguson, CEO, Global Holdings, Inc. states, "We believe that this dual-chamber syringe technology allows health care providers to deliver multiple drugs more quickly while helping insure the patient receives the proper medication in the proper sequence."
Immediately upon regulatory clearance, Global Holding’s introduction of "ChaSyr," a pre-filled, dual-chamber syringe, to the US market shall commence.
"ChaSyr" syringes’ unique, patented technologies have the potential to dramatically improve the delivery of IV medications, reduce the risk of medical errors and hospital-acquired infection.
A sequential dose, multi-chamber patented "ChaSyr" syringe improves speed and safety of drug deliveries while reducing health care costs.